WITHDRAWN: The impact of chromium supplementation on carbohydrates, liver function, kidney function and testosterone levels in diabetic rats

Abstract

Trivalent chromium (Cr III) can improve glucose absorption in fat cells of rats, and chromium supplementation may have therapeutic value for type II diabetes. In this study the impact of chromium supplementation on biochemical including carbohydrates, lipids, kidney function, liver function, and testosterone was examined in a diabetic rat. Wistar albino rats were divided into three groups of 10 rats each. Rats in Group A were untreated and served as the non-diabetic control. Rats in Group B and C were treated with a 60 mg/kg streptozotocin intraperitoneally injection to induce diabetes and those in Group C also received 120 mcg chromium picolinate. Induction of diabetes 3 days after streptozotocin (STZ) treatment was confirmed in Groups B and C by measurement of fasting blood suger levels with a glucometer. Animals having blood sugar levels >200 mg/dL were considered to be diabetic. rats with diabetes also exhibited other diabetes symptoms such as polyuria, polydipsia and glycosuria. The control Group A non-diabetic and diabetic STZ Group B had average glucose levels of 139.0±27.0 mg/dl and 460.9±122.0 mg/dl, respectively. Chromium supplementation substantially decreased glucose levels relative to the diabetes group to 251.9±30.0 mg/dl. For lipid profiles, chromium supplementation was associated with significant reductions in HDL levels and in potassium levels in kidney function tests. Testosterone levels were significantly increased with chromium supplementation. Taken together, chromium supplementation acts at various levels to mitigate diabetes symptoms as reflected by reduced glucose levels, HDL levels and potassium levels, as well as increased testosterone levels.